खोज परिणाम - Eric J. Feldman

  • प्रदर्शित 1 - 20 परिणाम 20
परिणाम को परिष्कृत करें
  1. 1
    The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase

    The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerase द्वारा XU Wen-qing, Karen Seiter, Eric J. Feldman, Tauseef Ahmed, JW Chiao

    प्रकाशित 1996
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  2. 2
    Prevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic Trioxide

    Prevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic Trioxide द्वारा Gail J. Roboz, Ellen K. Ritchie, Rebecca F. Carlin, Michael S. Samuel, Leanne Gale, Juliette L. Provenzano-Gober, Tania J. Curcio, Eric J. Feldman, Paul Kligfield

    प्रकाशित 2014
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  3. 3
    Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia

    Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia द्वारा Bethan Psaila, James B. Bussel, Andrew L. Frelinger, Bracken Babula, Matthew D. Linden, Y. LI, M.R. BARNARD, Christian Tate, Eric J. Feldman, Alan D. Michelson

    प्रकाशित 2011
    पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  4. 4
    Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia

    Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia द्वारा Ellen K. Ritchie, Eric J. Feldman, Paul J. Christos, Sarah D. Rohan, Catherine B. Lagassa, Cindy Ippoliti, Joseph M. Scandura, Karen-Sue Carlson, Gail J. Roboz

    प्रकाशित 2012
    पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  5. 5
    The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death

    The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death द्वारा Isabelle Petit, Matthias A. Karajannis, Loi͏̈c Vincent, Lauren M. Young, Jason M. Butler, Andrea T. Hooper, Koji Shido, Hermann Steller, David J. Chaplin, Eric J. Feldman, Shahin Rafii

    प्रकाशित 2007
    पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  6. 6
    Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia

    Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia द्वारा Daniel J. DeAngelo, Brian A. Jonas, Jane L. Liesveld, Dale L. Bixby, Anjali S. Advani, Paula Marlton, John L. Magnani, Helen Thackray, Eric J. Feldman, Michael O’Dwyer, Pamela S. Becker

    प्रकाशित 2021
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  7. 7
    First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

    First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leuk... द्वारा Eric J. Feldman, Jeffrey E. Lancet, Jonathan E. Kolitz, Ellen K. Ritchie, Gail J. Roboz, Alan F. List, Steven L. Allen, Ekatherine Asatiani, Lawrence D. Mayer, Christine E. Swenson, Arthur C. Louie

    प्रकाशित 2011
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  8. 8
    Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML

    Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML द्वारा Joseph M. Scandura, Gail J. Roboz, Michelle Moh, Ewelina Morawa, Fabienne Brenet, Jahar R Bose, Luis Juárez Villegas, Usama Gergis, Sebastian Mayer, Cindy Ippoliti, Tania J. Curcio, Ellen K. Ritchie, Eric J. Feldman

    प्रकाशित 2011
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  9. 9
    Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias

    Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias द्वारा Ivana Gojo, Mariola Sadowska, Alison Walker, Eric J. Feldman, Swaminathan P. Iyer, Maria R. Baer, Edward A. Sausville, Rena G. Lapidus, Da Zhang, Yali Zhu, Ying-Ming Jou, Jennifer Poon, Karen Small, Rajat Bannerji

    प्रकाशित 2013
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  10. 10
    Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

    Phase II, multicenter, randomized trial of CPX‐351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML द्वारा Jorge E. Cortés, Stuart L. Goldberg, Eric J. Feldman, David Rizzeri, Donna E. Hogge, Melissa L. Larson, Arnaud Pigneux, Christian Récher, Gary J. Schiller, Krzysztof Warzocha, Hagop M. Kantarjian, Arthur C. Louie, Jonathan E. Kolitz

    प्रकाशित 2014
    पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  11. 11
    Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

    Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML द्वारा Jeffrey E. Lancet, Jorge E. Cortés, Donna E. Hogge, Martin S. Tallman, Tibor Kovacsovics, Lloyd E. Damon, Rami S. Komrokji, Scott R. Solomon, Jonathan E. Kolitz, Maureen Cooper, Andrew M. Yeager, Arthur C. Louie, Eric J. Feldman

    प्रकाशित 2014
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  12. 12
    Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium

    Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): Formal recommendations from the post-myel... द्वारा John Mascarenhas, Mark Heaney, Vesna Najfeld, Elizabeth O. Hexner, Omar Abdel‐Wahab, Raajit K. Rampal, Farhad Ravandi, Bruce Petersen, Gail J. Roboz, Eric J. Feldman, Nikolai A. Podoltsev, Dan Douer, Ross L. Levine, Martin S. Tallman, Ronald Hoffman

    प्रकाशित 2012
    पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  13. 13
    A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

    A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia द्वारा Jeffrey E. Lancet, Ivana Gojo, Jason Gotlib, Eric J. Feldman, Jacqueline M. Greer, Jane L. Liesveld, Laura M. Bruzek, Lawrence E. Morris, Youn Park, Alex A. Adjei, Scott H. Kaufmann, Elizabeth Garrett‐Mayer, Peter L. Greenberg, James R. Wright, Judith E. Karp

    प्रकाशित 2006
    पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  14. 14
    Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

    Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion द्वारा Alan F. List, Gordon W. Dewald, John M. Bennett, Aristoteles Giagounidis, Azra Raza, Eric J. Feldman, Bayard L. Powell, Peter L. Greenberg, Deborah A. Thomas, Richard M. Stone, Craig B. Reeder, Kenton Wride, John Patin, M. Schmidt, Jerome B. Zeldis, Robert Knight

    प्रकाशित 2006
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  15. 15
    Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies

    Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies द्वारा Peter Martin, Amy Chadburn, Paul J. Christos, Richard R. Furman, Jia Ruan, Malea Joyce, E Fusco, Patricia Glynn, Rebecca Elstrom, Rubén Niesvizky, Eric J. Feldman, Tsiporah B. Shore, Michael W. Schuster, Scott Ely, D M Knowles, Selina Chen‐Kiang, Morton Coleman, John P. Leonard

    प्रकाशित 2008
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  16. 16
    Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

    Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-R... द्वारा Thomas Fischer, Richard M. Stone, Daniel J. DeAngelo, Ilene Galinsky, Elihu H. Estey, Carlo Lanza, Edward Fox, Gerhard Ehninger, Eric J. Feldman, Gary J. Schiller, Virginia M. Klimek, Stephen D. Nimer, D. Gary Gilliland, Catherine Dutreix, Alice Huntsman-Labed, J. D. Virkus, Francis J. Giles

    प्रकाशित 2010
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  17. 17
    Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia

    Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refrac... द्वारा Eric J. Feldman, Joseph Brandwein, Richard M. Stone, Matt Kalaycio, Joseph O. Moore, Julie O’Connor, Nancy Wedel, Gail J. Roboz, Carole B. Miller, Raj Chopra, Joseph C. Jurcic, Randy A. Brown, W. Christopher Ehmann, Philip Schulman, Stanley R. Frankel, Daniel De Angelo, David A. Scheinberg

    प्रकाशित 2005
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  18. 18
    Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain

    Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain द्वारा Florian H. Heidel, Fian K. Solem, Frank Breitenbuecher, Daniel B. Lipka, Stefan Kasper, Melanie Thiede, Christian Brandts, Hubert Serve, Johannes Roesel, Francis J. Giles, Eric J. Feldman, Gerhard Ehninger, Gary J. Schiller, Stephen D. Nimer, Richard M. Stone, Yanfeng Wang, Thomas Kindler, Pamela Cohen, Christoph Huber, Thomas Fischer

    प्रकाशित 2005
    पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  19. 19
    Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

    Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q द्वारा Azra Raza, James A. Reeves, Eric J. Feldman, Gordon W. Dewald, John M. Bennett, H. Joachim Deeg, Luke Dreisbach, Charles A. Schiffer, Richard M. Stone, Peter L. Greenberg, Peter Curtin, Virginia M. Klimek, Jamile M. Shammo, Deborah A. Thomas, Robert Knight, M. Schmidt, Kenton Wride, Jerome B. Zeldis, Alan F. List

    प्रकाशित 2007
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:
  20. 20
    Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia

    Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia द्वारा Fu Li, May Kung Sutherland, Changpu Yu, Roland B. Walter, Lori Westendorf, John Valliere‐Douglass, Lucy Pan, Ashley Cronkite, Django Sussman, Kerry Klussman, Michelle Ulrich, Martha E. Anderson, Ivan J. Stone, Weiping Zeng, Mechthild Jonas, Timothy S. Lewis, Maitrayee Goswami, Sa A. Wang, Peter D. Senter, Che-Leung Law, Eric J. Feldman, Dennis R. Benjamin

    प्रकाशित 2017
    पूर्ण पाठ प्राप्त करें पूर्ण पाठ प्राप्त करें
    Artigo
    सूची में सहेजें
    में बचाया:

खोज साधन: